Survival and Economic Impact of Rapid Prostate-Specific Antigen Doubling Time in Patients With Nonmetastatic Castration-Resistant Prostate Cancer.
暂无分享,去创建一个
S. Freedland | N. Janjan | D. George | K. Ramaswamy | J. Mardekian | N. Schultz | R. Sandin | Ahong Huang
[1] A. Jemal,et al. Cancer statistics for African American/Black People 2022 , 2022, CA: a cancer journal for clinicians.
[2] R. Ionescu-Ittu,et al. Real-World Treatment Patterns and Overall Survival of Patients with Metastatic Castration-Resistant Prostate Cancer in the US Prior to PARP Inhibitors , 2021, Advances in Therapy.
[3] K. Aben,et al. The effects of new life-prolonging drugs for metastatic castration-resistant prostate cancer (mCRPC) patients in a real-world population , 2021, Prostate Cancer and Prostatic Diseases.
[4] W. Lowrance,et al. Advanced Prostate Cancer: AUA/ASTRO/SUO Guideline PART II. , 2020, The Journal of urology.
[5] S. Shariat,et al. Apalutamide, enzalutamide, and darolutamide for non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis , 2020, International Journal of Clinical Oncology.
[6] T. Tammela,et al. Nonmetastatic, Castration-Resistant Prostate Cancer and Survival with Darolutamide. , 2020, The New England journal of medicine.
[7] F. Saad,et al. Apalutamide and Overall Survival in Prostate Cancer. , 2020, European urology.
[8] S. Freedland,et al. Predictors of survival, healthcare resource utilization, and healthcare costs in veterans with non-metastatic castration-resistant prostate cancer. , 2020, Urologic oncology.
[9] F. Saad,et al. Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer. , 2020, The New England journal of medicine.
[10] K. Tangirala,et al. A Retrospective Claims Analysis of Advanced Prostate Cancer Costs and Resource Use , 2019, PharmacoEconomics - Open.
[11] F. Saad,et al. Patient-reported outcomes following enzalutamide or placebo in men with non-metastatic, castration-resistant prostate cancer (PROSPER): a multicentre, randomised, double-blind, phase 3 trial. , 2019, The Lancet. Oncology.
[12] T. Tammela,et al. Darolutamide in Nonmetastatic, Castration‐Resistant Prostate Cancer , 2019, The New England journal of medicine.
[13] W. Oyen,et al. Managing Nonmetastatic Castration-resistant Prostate Cancer. , 2019, European urology.
[14] F. Saad,et al. Effect of apalutamide on health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: an analysis of the SPARTAN randomised, placebo-controlled, phase 3 trial. , 2018, The Lancet. Oncology.
[15] F. Saad,et al. Enzalutamide in Men with Nonmetastatic, Castration‐Resistant Prostate Cancer , 2018, The New England journal of medicine.
[16] F. Saad,et al. Apalutamide Treatment and Metastasis‐free Survival in Prostate Cancer , 2018, The New England journal of medicine.
[17] M. Terris,et al. Thresholds for PSA doubling time in men with non‐metastatic castration‐resistant prostate cancer , 2017, BJU international.
[18] M. Terris,et al. Predicting bone scan positivity in non-metastatic castration-resistant prostate cancer , 2015, Prostate Cancer and Prostatic Disease.
[19] F. Saad,et al. Denosumab and bone metastasis-free survival in men with nonmetastatic castration-resistant prostate cancer: exploratory analyses by baseline prostate-specific antigen doubling time. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] E. Horwitz,et al. Prostate-specific antigen doubling time predicts the development of distant metastases for patients who fail 3-dimensional conformal radiotherapy or intensity modulated radiation therapy using the Phoenix definition , 2011 .
[21] J. Nelson,et al. Disease and host characteristics as predictors of time to first bone metastasis and death in men with progressive castration‐resistant nonmetastatic prostate cancer , 2011, Cancer.
[22] M. Terris,et al. Does PSADT after radical prostatectomy correlate with overall survival?--a report from the SEARCH database group. , 2011, Urology.
[23] F. Saad,et al. Guidelines for the management of castrate-resistant prostate cancer , 2010 .
[24] A. D'Amico,et al. Prostate Specific Antigen Doubling Time , 2008 .
[25] Susan Halabi,et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] H. Quan,et al. Coding Algorithms for Defining Comorbidities in ICD-9-CM and ICD-10 Administrative Data , 2005, Medical care.
[27] F. Saad,et al. Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[28] Ming-Hui Chen,et al. Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy. , 2003, Journal of the National Cancer Institute.
[29] A W Partin,et al. Natural history of progression after PSA elevation following radical prostatectomy. , 1999, JAMA.